EUVIMEDOpdag EUVIMED
VergleichsstudieQuerschnittstudieOpen access · CC BY 4.0

Bilirubin interference in creatinine assays: cross-sectional analysis of the impact on the MELD score and CKD staging using Jaffe vs enzymatic methods

Kathrin Frey, Joanna Gawinecka, Arnold Von Eckardstein, Lanja Saleh

Swiss Medical Weekly · 2026-02-25 · 156 (2) · 4707

DOI: 10.57187/4707 ↗

At a glance

Vergleichsstudie in Swiss Medical Weekly, published online on 2026-02-25. Written by Kathrin Frey and 3 co-authors. Institution: Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland. Major MEDLINE topics: Bilirubin, Creatinine, Kidney Function Tests, Renal Insufficiency, Chronic. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND: Reliable and accurate measurement of creatinine is essential for the estimation of kidney function (eGFR) and for survival prediction with the model of the end-stage liver disease (MELD) score. Bilirubin interference is considered an important interference of Jaffe creatinine assays; the enzymatic assay is also affected but less so. This study aimed to evaluate the comparability of the Jaffe and enzymatic creatinine methods and the impact of their discrepancy on clinical decision-making, particularly in the context of bilirubin interference. METHODS: We compared creatinine measurements from the Roche Jaffe Gen.2 (CREJ2) and Roche Creatinine Plus ver.2 (CREP2) assays using routine heparin plasma samples (n = 15,618). To estimate the clinical impact of bilirubin interference on these two assays, we evaluated our results in the context of eGFR-based staging of severity of kidney disease and the MELD score. RESULTS: The Roche Jaffe and enzymatic methods agree well for non-icteric samples with a mean relative bias of 3.97% but not in icteric samples. In samples with 5–20 mg/dl and 20–53 mg/dl bilirubin, the biases amounted to 10.9% and 43.4%, respectively. CONCLUSIONS: The Jaffe method’s susceptibility to bilirubin interference, in comparison to the enzymatic assay, can result in higher MELD scores and can lead to an underestimation of kidney function.

Subjects

MeSH terms (MEDLINE)

BilirubinCreatinineKidney Function TestsRenal Insufficiency, ChronicEnd Stage Liver DiseaseHumansCross-Sectional StudiesSeverity of Illness IndexGlomerular Filtration RateFemale

Substances

BilirubinCreatinine

Authors and institutions

  • Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland.
  • Institute for Laboratory Medicine, Triemli Hospital, Zurich, Switzerland.

Cite

APA

Frey, K., Gawinecka, J., Von Eckardstein, A., & Saleh, L. (2026). Bilirubin interference in creatinine assays: cross-sectional analysis of the impact on the MELD score and CKD staging using Jaffe vs enzymatic methods. Swiss Medical Weekly, 156(2), 4707. https://doi.org/10.57187/4707

Vancouver

Frey K, Gawinecka J, Von Eckardstein A, Saleh L. Bilirubin interference in creatinine assays: cross-sectional analysis of the impact on the MELD score and CKD staging using Jaffe vs enzymatic methods. Swiss Medical Weekly. 2026;156(2):4707. doi:10.57187/4707

BibTeX
@article{Frey2026,
  author = {Frey, Kathrin and Gawinecka, Joanna and Von Eckardstein, Arnold and Saleh, Lanja},
  title = {Bilirubin interference in creatinine assays: cross-sectional analysis of the impact on the MELD score and CKD staging using Jaffe vs enzymatic methods},
  journal = {Swiss Medical Weekly},
  year = {2026},
  volume = {156},
  number = {2},
  pages = {4707},
  doi = {10.57187/4707}
}
Start for free →